Lessons from $800-million drug flop may lead to a new genre of anti-cholesterol medicines
2012-02-23
(Press-News.org) Mindful of lessons from a failed heart drug that cost $800 million to develop, drug companies are taking another shot at new medications that boost levels of so-called "good cholesterol," which removes cholesterol from the body. A report on how three new versions of medications in the same family as the failed torcetrapib appears in the current edition of Chemical & Engineering News, the newsmagazine of the American Chemical Society, the world's largest scientific society.
In the cover story, C&EN Associate Editor Carmen Drahl explains that the drug maker Pfizer abruptly stopped development of its newest heart medicine in 2006, when clinical trials showed it was increasing patients' risk of death. Torcetrapib then was a high-profile potential new medication that blocked a substance called cholesteryl ester transfer protein (CETP) in a way expected to increase blood levels of HDL-cholesterol, high-density lipoprotein cholesterol. Experts hoped torcetrapib would open a new chapter in treating heart disease. Data, however, indicated that torcetrapib had increased the risk of death in a 15,000-patient clinical trial, and Pfizer promptly halted further development.
C&EN describes how Eli Lilly, Roche and Merck slowed down development of their own CETP blockers to watch closely for hints unwanted of effects, such as torcetrapib's tendency to increase blood pressure, which Pfizer had missed. So far, the new CETP blockers continue to show promise as viable new heart drugs. Drahl points out, however, that the final judgment may be years away as results of clinical trials on 30,000 become available.
INFORMATION:
The American Chemical Society is a nonprofit organization chartered by the U.S. Congress. With more than 164,000 members, ACS is the world's largest scientific society and a global leader in providing access to chemistry-related research through its multiple databases, peer-reviewed journals and scientific conferences. Its main offices are in Washington, D.C., and Columbus, Ohio.
To automatically receive news releases from the American Chemical Society contact newsroom@acs.org.
END
ELSE PRESS RELEASES FROM THIS DATE:
2012-02-23
Tampa, Fla. (Feb. 22, 2012) – Increasingly, institutions of higher learning are including faculty member patents and commercialization activities in their calculus for offering tenure and promotion. However, a report published in Volume 13 Number 3 of Technology and Innovation, Proceedings of the National Academy of Inventors® finds that 75 percent of institutions surveyed do not include patent and commercialization considerations in their tenure and promotion criteria.
"Texas A&M University created quite a stir in May 2006 when it added commercialization considerations ...
2012-02-23
Inflammation, cell division and cell differentiation that occur during skeletal muscle regeneration may provide an ideal environment for the highly malignant tumor, rhabdomyosarcoma to arise. These are the findings from a Nationwide Children's Hospital study that examined rhabdomyosarcoma growth in mouse models of muscular dystrophy. The new models could help investigators search for factors that drive tumor growth and help test new therapies.
Rhabdomyosarcoma (RMS) is a fast-growing, highly-malignant tumor and is the most common soft tissue sarcoma in children and adolescents. ...
2012-02-23
LEXINGTON, Ky. (Feb. 22, 2012) — The University of Kentucky has announced that Dr. Daret St. Clair, the James Graham Brown Endowed Chair and professor of toxicology, has published the first comprehensive study that provides insight into the relationship between two types of suppressors in cancerous tumors. The results will enhance the understanding of transcriptional mechanisms in carcinogenesis.
The study was supported by a National Cancer Institute research grant and was recently published in Cancer Research. St. Clair and her team generated transgenic mice expressing ...
2012-02-23
To address the faculty shortage problem, schools of nursing are reexamining how they provide clinical education to undergraduate students to find ways to use faculty resources more efficiently so they can maintain student enrollment and meet the future need for nurses.
To this end, researchers from the New York University College of Nursing (NYUCN), funded with a grant from the Robert Wood Johnson Foundation's Evaluating Innovations in Nursing Education Program, have just published a description of an evaluation study, "Shifting the Clinical Teaching Paradigm in Undergraduate ...
2012-02-23
The manager of TDS Insurance discovered Islamaphobic vandalism on his store and reported it to police, reported the New York Daily News (2/9/2012). The apparent New York hate crime incident occurred last week.
"'Allah is s--t,'" said the anti-Muslim graffiti, according to the New York Daily News.
As reported by the tabloid, Bangladeshis in Kensington said they are now "living in fear" and "emotionally scarred" as a result of the apparent hate crime.
"Hate crime is not acceptable," said New York civil rights violation lawyer ...
2012-02-23
Philadelphia, PA, February 22, 2012 – Mild traumatic brain injury (TBI) and posttraumatic stress disorder (PTSD) are cardinal injuries associated with combat stress, and TBI increases the risk of PTSD development. The reasons for this correlation have been unknown, in part because physical traumas often occur in highly emotional situations.
However, scientists at University of California at Los Angeles provide new evidence from an animal model of a mechanistic link underlying the association between TBI and PTSD-like conditions.
Using procedures to separate the physical ...
2012-02-23
NEW YORK – February 22, 2012 – Research on the relationship between teacher characteristics and teacher effectiveness has been underway for over a century, yet little progress has been made in linking teacher quality with factors observable at the time of hire. A recent study by Columbia Business School's Prof. Jonah Rockoff, Sidney Taurel Associate Professor of Business, Finance and Economics; Brian Jacob, Walter H. Annenberg Professor of Education Policy, Gerald R. Ford School of Public Policy, University of Michigan; Thomas Kane, Professor of Education and Economics, ...
2012-02-23
Separating complex mixtures of cells, such as those found in a blood sample, can offer valuable information for diagnosing and treating disease. However, it may be necessary to search through billions of other cells to collect rare cells such as tumor cells, stem cells or fetal cells. "You're basically looking for a needle in a haystack," says Sukant Mittal, a graduate student in the Harvard-MIT Division of Health Sciences and Technology (HST).
Mittal and his colleagues at MIT and Massachusetts General Hospital (MGH) have now demonstrated a new microfluidic device that ...
2012-02-23
New Orleans, LA – Glen Palmer, PhD, Assistant Professor of Microbiology, Immunology & Parasitology at LSU Health Sciences Center New Orleans, was part of an international research team led by Luigina Romani, MD, at the University of Perugia, that discovered opportunistic fungi like Candida albicans can sense the immune status of host cells and adapt, evading immune system defenses. Unlike previous studies, this research investigated both sides of the infection equation as well as the interaction between the fungi and the cells they will invade. The findings are published ...
2012-02-23
4t Networks, a managed virtual hosting company based in metro Atlanta, is pleased to announce that it now offers Parallels Plesk Panel 10.4 for both its VPS hosting and Cloud hosting clients.
"We couldn't wait for the latest version of Plesk to be released," says Kevin Gray, President of 4t Networks. "We find that Parallels Plesk Panel 10.4 continues the improvements that were started with the release of Plesk 10."
Parallels Plesk Panel 10.4 gives clients an intuitive interface to control the management of their Virtual Private Servers and their ...
LAST 30 PRESS RELEASES:
[Press-News.org] Lessons from $800-million drug flop may lead to a new genre of anti-cholesterol medicines
